Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00048321 | ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis | PHASE2 | COMPLETED | 160 | — | — | Jan 1, 2002 | Feb 1, 2003 | Dec 5, 2022 | 31 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| ISIS 104838 | DRUG | - |
Inclusion Criteria 1. Age \>/= 18 years. 2. Rheumatoid arthritis for \>/= 6 months. 3. Active disease as defined by \>/= 6 swollen and \>/= 9 tender joints, AND an abnormal C-reactive protein or Westergren Erythrocyte Sedimentation Rate lab test, OR Morning Stiffness \>/= 1 hour. 4. Use of at least...